(Q46076481)

19 December 2017

title

Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine (English)

1 reference

19 December 2017

positron emission tomography

main subject

1 reference

1

1 reference

19 December 2017

Changxian Shen

object named as

Changxian Shen

3

0 references

Markus Schwaiger

object named as

Markus Schwaiger

5

0 references

Tobias Dechow

4

object named as

Tobias Dechow

1 reference

19 December 2017

author name string

Ken Herrmann

2

1 reference

19 December 2017

Hans-Jürgen Wester

6

1 reference

19 December 2017

publication date

24 March 2009

1 reference

19 December 2017

published in

Methods

1 reference

19 December 2017

volume

48

1 reference

19 December 2017

issue

2

1 reference

19 December 2017

page(s)

205-215

1 reference

19 December 2017

Positron-emission tomography and assessment of cancer therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Measuring the clinical response. What does it mean?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Biological characterisation of breast cancer by means of PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

The metabolism and fate of tritiated thymidine in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Ki-67 Staining as a Means to Simplify Analysis of Tumor Cell Proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Tumor imaging using 1-(2'-deoxy-2'-18F-fluoro-beta-D-arabinofuranosyl)thymine and PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

[18F]FBAU 3',5'-dibenzoate, a lipophilic prodrug, enhances brain uptake of the cell proliferation tracer [18F]FBAU.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Early changes in [18F]FLT uptake after chemotherapy: an experimental study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Molecular imaging of proliferation in malignant lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Positron emission tomography in patients with breast cancer using (18)F-3'-deoxy-3'-fluoro-l-thymidine ((18)F-FLT)-a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

[18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Evaluation of primary brain tumors with FLT-PET: usefulness and limitations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Clinical relevance of imaging proliferative activity in lung nodules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Potential impact of [ 18 F]3'-deoxy-3'-fluorothymidine versus [ 18 F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Detection and grading of soft tissue sarcomas of the extremities with (18)F-3'-fluoro-3'-deoxy-L-thymidine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

FLT-PET imaging of radiation responses in murine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Functional imaging for early prediction of response to chemoradiotherapy: 3'-deoxy-3'-18F-fluorothymidine positron emission tomography--a clinical application model of esophageal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.03.009

10.1016/J.YMETH.2009.03.009

7 January 2021

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

19318128

1 reference

19 December 2017